Related references
Note: Only part of the references are listed.Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs
Ferhana Y. Ali et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
NF-κB inhibitors impair platelet activation responses
E. Malaver et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus -: An effect probably mediated by direct platelet PPARγ activation
M. P. Khanolkar et al.
ATHEROSCLEROSIS (2008)
A dual role for integrin-linked kinase in platelets: regulating integrin function and α-granule secretion
Katherine L. Tucker et al.
BLOOD (2008)
Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation
Sarah Jones et al.
BLOOD (2008)
Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone
Voahanginirina Randriamboavonjy et al.
CIRCULATION (2008)
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes
Lorraine L. Lipscombe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus
C. I. Jones et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets
Leonardo A. Moraes et al.
BLOOD (2007)
The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPAR gamma ligands
Jamie J. O'Brien et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus
WH Sauer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus
BK Irons et al.
PHARMACOTHERAPY (2006)
Platelet PECAM-1 inhibits thrombus formation in vivo
S Falati et al.
BLOOD (2006)
Peroxisome proliferator-activated receptors and inflammation
Leonardo A. Moraes et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Ligand-specific glucocorticoid receptor activation in human platelets
LA Moraes et al.
BLOOD (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
The effects of PPAR-γ ligand pioglitazone on platelet aggregation and arterial thrombus formation
DY Li et al.
CARDIOVASCULAR RESEARCH (2005)
Nongenomic effects of 17 beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor and Src kinase
L Moro et al.
BLOOD (2005)
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes
DK McGuire et al.
AMERICAN HEART JOURNAL (2004)
Peroxisome proliferator-activated receptor γ:: Implications for cardiovascular disease
WA Hsueh et al.
HYPERTENSION (2004)
Platelets: signaling cells in the immune continuum
AS Weyrich et al.
TRENDS IN IMMUNOLOGY (2004)
Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes
F Akbiyik et al.
BLOOD (2004)
Platelet adhesion signalling and the regulation of thrombus formation
JM Gibbins
JOURNAL OF CELL SCIENCE (2004)
Platelet-collagen interaction: is GPVI the central receptor?
B Nieswandt et al.
BLOOD (2003)
Nongenomic steroid action:: Controversies, questions, and answers
RM Lösel et al.
PHYSIOLOGICAL REVIEWS (2003)
Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components, of the glycoprotein VI signaling pathway
GP Hubbard et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency
MC Chapelsky et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management
JA Beckman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells
JD Croxtall et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets
M Cicmil et al.
BLOOD (2002)
Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen
S Patil et al.
BLOOD (2001)
Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
G Chinetti et al.
INFLAMMATION RESEARCH (2000)
Share Paper
